NCT06349668招募中3 期
SMILe: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery
Hans Bahlmann3 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2024年4月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 220
- 试验地点
- 3
- 主要终点
- QoR-15 score at postoperative day 1
研究概览
简要总结
The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:
- Is the decrease in wellbeing as quantified by the patient-centered outcome scale "Quality of Recovery 15" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia?
- Does spinal analgesia result in improved recovery as quantified by QoR-15 at POD 7, the incidence of postoperative pain at rest and at mobilization, nausea and vomiting, the need for opioid analgesics, time out-of-bed, length of stay and the incidence of complications?
- Does spinal analgesia increase workload in the OR, as quantified by time from arrival in the OR to start of surgery?
- Does spinal analgesia result in an increased incidence of hypotension and cardiac dysfunction during surgery, as well as an increased incidence of pruritus after surgery?
Participants will be randomized to receive either spinal analgesia with bupivacaine and morphine preoperatively or an intravenous infusion with lidocaine intraoperatively.
QoR-15 and other markers of recovery will be registered using structured interviews preoperatively, at POD1 and POD7. In addition, patients will record pain at rest and at mobilization three times daily in a diary.
In a subgroup of patients advanced hemodynamic parameters will be recorded using pulse-contour analysis before, during and after surgery. Blood samples will also be collected in these patients at fixed intervals and analyzed for amongst others inflammation and cardiac dysfunction.
详细描述
Please refer to CTIS
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is scheduled for elective robotic-assisted upper urinary tract surgery at one of the participating hospitals
- •The patient gives oral and written informed consent after having received oral and writen information about the study
排除标准
- •The patient has a ASA-class of IV or above
- •The patient is a minor or declared incompetent, has severe psychiatric disease or is expected not to be able to understand the study information due to severe restrictions in vision, hearing, cognition, reading or Swedish language abilities
- •The patient is a female who is pregnant or breastfeeding
- •The patient is a pre-menopausal female who has not undergone sterilisation, hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy, and is not using highly-effective contraception with low user-dependency and cannot provide a negative pregnancy test
- •The patient is scheduled for emergency surgery
- •Research staff not available
- •Scheduled significant simultaneous surgery on another organ
- •The anesthesiologist in charge has planned spinal or epidural analgesia
- •The patient has clear contraindications to spinal analgesia, e.g. severe coagulopathy, severe aortic stenosis, previous back surgery with rods, or spinal analgesia can be expected to be technically challenging (severe obesity, severe scoliosis)
- •The patient has clear contraindications to lidocaine infusion, e.g. proven allergy to local anesthetics, myasthenia gravis, renail failure (eGFR < 30), hepatic failure caused by acute hepatitis or cirrhosis (Child-Pugh B or higher, severe cardiac arrythmias or insuffiency (NYHA IIIb or higher)
- •The patient has previously participated in the trial
研究组 & 干预措施
spinal analgesia
Experimental
single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
干预措施: spinal analgesia with morphine and bupivacaine (Drug)
lidocaine infusion
Active Comparator
intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
干预措施: lidocaine infusion (Drug)
结局指标
主要结局
QoR-15 score at postoperative day 1
时间窗: First day after surgery
Quality of Recovery-15 score ranges from 0 to 150 with 0 reflecting zero wellbeing and 150 reflecting perfect wellbeing. The primary research hypothesis is that the reduction in QoR-15 from baseline before surgery to the first postoperative day (POD 1) is at least 8.0 points less in the morphine spinal group compared to the control group treated with intravenous lidocaine.
次要结局
- Pain (NRS) in rest and during motion at POD 7(Seventh day after surgery)
- QoR-15 score preoperatively(Any time between inclusion and the night before surgery)
- QoR-15 score at postoperative day 7(Seventh day after surgery)
- Pain (NRS) on POD 1-3(First, second and third day after surgery)
- Length of stay(From first until thirtieth day after surgery)
- Requirement for opioids after discharge(From first until seventh day after surgery)
- Intraoperative Cardiac Index(Intraoperative)
- Intraoperative Pulse Pressure Variation(Intraoperative)
- Amount of remifentanil in patients given remifentanil(Intraoperatively)
- Amount of intraoperative opioids in patients not receiving remifentanil(Intraoperatively)
- DAOH30(From first until thirtieth day after surgery)
- Intraoperative dynamic arterial elastance(Intraoperative)
- Intraoperative Cardiac Power Index(Intraoperative)
- Intraoperative Systemic Vascular Resistance Index(Intraoperative)
- Intraoperative fluid balance(Intraoperatively)
- Intraoperative Stroke Volume Index(Intraoperative)
- Intraoperative Stroke Volume Variation(Intraoperative)
- Intraoperative dPmx(Intraoperative)
- Biochemical markers of inflammation(Day of surgery and first and third day after surgery.)
- Time from arrival in the OR to start of surgery(Time from entering the OR to first incision or start of endoscopy, whichever comes first, up to 4 hrs.)
- Time from end of surgery until leaving the OR(Time from end of surgery (removing of surgical drapes or finishing of endoscopy, whichever comes last) until leaving the OR, up to 4 hrs)
- Incidence of unplanned termination of the lidocaine infusion(Intraoperatively)
- "Time out-of-bed" on POD 1-3(First, second and third day after surgery)
- First POD passing gases(From first until seventh day after surgery)
- First POD passing stool(From first until seventh day after surgery)
- Incidence of pruritus(From first until seventh day after surgery)
- Postoperative complications untill POD 30(From first until thirtieth day after surgery)
- Incidence of respiratory depression leading to the use of a mu-antagonist within 48 hours of induction of anesthesia(From induction of anesthesia until 48 hours after induction of anesthesia)
- Time with low blood pressure during anesthesia(Intraoperatively)
- Lowest MAP within 10 minutes after induction of anesthesia(Within 10 minutes after induction of anesthesia)
- Intraoperative heart rate(Intraoperative)
- Pain (NRS) in rest and during motion 2hrs after arrival to the PACU/ICU/HDU(2 hrs after arrival to the PACU)
- Length of stay at the PACU/ICU/HDU(Length of stay at the PACU (from first to final recording of any vital sign by the electronic patient data management system), up to 30 days)
- Amount of opioids administred at the PACU/ICU/HDU during the first 24 hrs after end of surgery(During stay at the PACU (from first to final recording of any vital sign by the electronic patient data management system), up to 30 days)
- PONV requiring treatment at 0-6 hours and 6-24 hours postoperatively as well as during the whole postoperative stay(At 0-6 hours and 6-24 hours postoperatively as well as during the whole postoperative stay)
- Amount of opioids administered during the first 24 hours at the PACU/ICU/HD and on the ward(During the first 24 hours at the PACU and on the ward)
- Highest MAP within 10 minutes of start of abdominal insufflation(Within 10 minutes of abdominal insufflation)
- Fraction of patients needing norepinephrine within 15 minutes after start of abdominal insufflation(From anesthesia induction until 15 minutes after start of abdominal insufflation)
- Fraction of patients needing norepinephrine intraoperatively (later than 15 minutes after start of abdominal insufflation)(Intraoperatively (later than 15 minutes after start of abdominal insufflation))
- Average infusion rate of norepinephrine, in patients receiving norepinephrine, before 15 minutes after start of abdominal insufflation(From anesthesia induction until 15 minutes after start of abdominal insufflation until end of anesthesiaon, up to 48 hours)
- Average infusion rate of norepinephrine, in patients receiving norepinephrine, after 15 minutes after start of abdominal insufflation(From 15 minutes after start of abdominal insufflation until end of anesthesia (extubation), up to 48 hrs)
研究者
Hans Bahlmann
Senior Consultant. Sponsor
University Hospital, Linkoeping
研究点 (3)
Loading locations...
相似试验
Unknown
4 期
Intrathecal Morphine and Local Infiltration Analgesia in Total Knee ArthroplastyPain, PostoperativeNCT03434951South Carelia Central Hospital120
暂停
4 期
Intrathecal Morphine vs. Intrathecal Morphine and Regional Anesthesia After Cesarean Section.Post-operative PainNCT06114121University of Miami100
招募中
4 期
Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery, a IMPACT-Scope TrialPatients Undergoing Major Laparoscopic Abdominal SurgeryNCT06666985First Affiliated Hospital, Sun Yat-Sen University700
已完成
不适用
Intrathecal Morphine in Knee ArthroplastyPain, PostoperativeArthroplasty, Replacement, KneeNCT00695045University College Hospital Galway60
已完成
4 期
Intravenous Paracetamol or Morphine for the Treatment of Acute Flank PainUrolithiasisNCT01318187Pamukkale University73